By evaluating molecules so that optimal drug forms are identified, and even allying this to optimal delivery mechanisms before the clinic, can ensure a greater chance of developmental success.
Stephen Tindal, Director of Science and Technology at Catalent, introduces the approach that the organisation offers its clients to achieve these goals.
According to industry reports, only ‘1 in 10 new molecules in active clinical development is readily bioavailable.’1 Even those that are may not be sufficiently absorbed when dosed at escalated levels. We know that, in addition, limited amounts of material are available for the determination of formulation pathways that would result in speedy product development.
The OptiForm Solution Suite is an integrated offering designed to efficiently and rapidly solve complex bioavailability challenges for early stage molecules using a unique toolkit of bioavailability enhancing technologies. OptiForm Solution Suite matches the best formulation technologies to a molecule, and utilises an accelerated parallel screening and development approach, based on rigorous science and best-in-class scientific expertise, all in 12 weeks.
By combining our vast experience in drug formulation with our market-leading toolkit of delivery technologies, including RP Scherer Softgels, micronisation capabilities, OptiMelt hot melt extrusion and the world’s leading orally dissolvable tablet (ODT), Zydis, rapid screening and assessment can quickly find solutions to small molecule formulation challenges.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.